These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21897329)

  • 1. Cellular therapy to treat haematological and other malignancies: progress and pitfalls.
    Fromm PD; Gottlieb D; Bradstock KF; Hart DN
    Pathology; 2011 Oct; 43(6):605-15. PubMed ID: 21897329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cellular immunotherapy for hematological malignancies].
    Yasukawa M
    Rinsho Ketsueki; 2008 Oct; 49(10):1460-71. PubMed ID: 18833930
    [No Abstract]   [Full Text] [Related]  

  • 3. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of hematological malignancies using dendritic cells.
    Van de Velde AL; Berneman ZN; Van Tendeloo VF
    Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell therapy: achievements and perspectives.
    Bordignon C; Carlo-Stella C; Colombo MP; De Vincentiis A; Lanata L; Lemoli RM; Locatelli F; Olivieri A; Rondelli D; Zanon P; Tura S
    Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically modified tumour vaccines--where we are today.
    Nawrocki S; Mackiewicz A
    Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation.
    Kim DH; Won DI; Lee NY; Sohn SK; Suh JS; Lee KB
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):719-28. PubMed ID: 16785061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of cancer using dendritic cells.
    Morse MA; Lyerly HK
    Cytokines Cell Mol Ther; 1998 Mar; 4(1):35-44. PubMed ID: 9557215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo expansion of hematopoietic cells and their clinical use.
    Aglietta M; Bertolini F; Carlo-Stella C; De Vincentiis A; Lanata L; Lemoli RM; Olivieri A; Siena S; Zanon P; Tura S
    Haematologica; 1998 Sep; 83(9):824-48. PubMed ID: 9825579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of hematological malignancy-associated antigens and clinical applications.
    Fujiwara H
    Rinsho Ketsueki; 2009 May; 50(5):340-51. PubMed ID: 19483393
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer-testis antigens in haematological malignancies.
    Meklat F; Li Z; Wang Z; Zhang Y; Zhang J; Jewell A; Lim SH
    Br J Haematol; 2007 Mar; 136(6):769-76. PubMed ID: 17223912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Immunotherapy by coordinated stimulation of innate lymphocytes (NK and NKT cells).
    Fujii S
    Rinsho Ketsueki; 2009 May; 50(5):364-74. PubMed ID: 19483396
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting tumours by adoptive transfer of immune cells.
    Macary PA; Too CT; Dai X
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):569-74. PubMed ID: 16700896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promiscuity of the AlloHLA-A2 restricted T cell repertoire hampers the generation of minor Histocompatibility antigen-specific cytotoxic T cells across HLA barriers.
    Oosten LE; Blokland E; Kester MG; Falkenburg JH; van Halteren AG; Goulmy E
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):151-63. PubMed ID: 17241921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer.
    Santin AD; Bellone S; Underwood LJ; O'Brien TJ; Ravaggi A; Pecorelli S; Cannon MJ
    Minerva Ginecol; 2002 Apr; 54(2):133-44. PubMed ID: 12032451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells in cancer immunotherapy.
    Gunzer M; Grabbe S
    Crit Rev Immunol; 2001; 21(1-3):133-45. PubMed ID: 11642600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell vaccines for the treatment of prostate cancer.
    Lehrfeld TJ; Lee DI
    Urol Oncol; 2008; 26(6):576-80. PubMed ID: 18996314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell therapy after hematopoietic stem cell transplantation.
    Kennedy-Nasser AA; Brenner MK
    Curr Opin Hematol; 2007 Nov; 14(6):616-24. PubMed ID: 17898565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.